Opendata, web and dolomites

Nyxoah

Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Nyxoah project word cloud

Explore the words cloud of the Nyxoah project. It provides you a very rough idea of what is the project "Nyxoah" about.

disruptive    economic    neurocognitive    mask    keep    neurostimulator    standards    loop    annual    prevalent    2009    invasive    implanted    device    morbidity    sleepiness    machine    wirelessly    patients    disease    mortality    chin    unpleasant    displays    healthcare    plan    trials    options    daytime    apnea    arrhythmia    acute    refuse    app    central    disposable    line    obstructive    linked    cardiovascular    continue    attack    security    noisy    obese    compliance    sleep    attached    nerve    stroke    outright    founded    public    outcome    pulse    industrialization    resistance    poor    smaller    smart    cloud    monitoring    synced    implant    regualatory    treatment    activation    ineffective    pressure    disorder    closed    first    depression    company    clinical    feedback    agencies    impacts    cardiac    detects    infection    stuck    patient    surgery    communicates    responds    lifelong    performance    efficacy    elderly    world    burnout    drawbacks    nyxoah    worldwide    patch    chip    50    cohorts    people    health    risk    social    chronic    neurostimulation    fail    reimbursement    heart    100m    tells    constant    150b    tissue    uncomfortable    physicians    powered    lower    implantations    cpap    tiny    therapeutic    adjust   

Project "Nyxoah" data sheet

The following table provides information about the project.

Coordinator
NYXOAH SA 

Organization address
address: RUE DU FOND CATTELAIN 2
city: MONT-SAINT-GUIBERT
postcode: 1435
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NYXOAH SA BE (MONT-SAINT-GUIBERT) coordinator 50˙000.00

Map

 Project objective

Obstructive Sleep Apnea is the world's most common sleep disorder and affects 100m people worldwide. It is particularly prevalent among elderly and obese cohorts and is a lifelong disease, with acute and chronic health impacts. It is linked to increased cardiovascular morbidity and mortality, and associated with increased risk of heart attack, cardiac arrhythmia, stroke, daytime sleepiness, depression and poor neurocognitive performance. Estimated annual economic costs of the disease are €60-150b. Established therapeutic options are uncomfortable with unpleasant side effects and/or ineffective; they can also require invasive surgery. Compliance is a major problem with the first line treatment, CPAP: 50% of users refuse it outright or fail to continue use after 1 year. Nyxoah's disruptive neurostimulation device responds directly to these needs and drawbacks. Central to the system is a tiny device implanted under the chin that - compared to other neurostimulator implantations - is smaller, less invasive and has lower risk of infection. The device is powered wirelessly by an activation chip, which is attached to a disposable smart patch and stuck under the chin before sleep. No mask, no noisy machine, no unpleasant side effects. The chip has a closed feedback loop with the implant, which detects tissue resistance and tells the chip to adjust the pulse to keep constant pressure on the nerve, to avoid burnout; it also communicates wirelessly with an app, which displays useful information (synced with the cloud) for use by patients, physicians and social security agencies; this is a key development to allow treatment compliance monitoring and therefore for reimbursement. During the Phase 1 project, the company, founded in 2009, will assess scale-up industrialization plan, product development according to regualatory standards and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NYXOAH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NYXOAH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More